Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07654426 · ClinicalTrials.gov registry record · Phase 2
The CARDIOPROTECT Trial
A Phase 2 study, sponsored by Beth Israel Deaconess Medical Center.
- Not yet
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT07654426 is a Phase 2 study that has not yet begun recruiting, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 60 participants.
The verdict
NCT07654426, a Phase 2 study, has not yet begun recruiting, sponsored by Beth Israel Deaconess Medical Center.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
This trial is to evaluate if dexrazoxane is safer and more effective than liposomal doxorubicin in preventing heart failure events in participants with diffuse large B-cell lymphoma (DLBCL) undergoing either standard of care R-CHOP or pola-R-CHP treatment regiments. The names of the study drugs involved in this study are: * Dexrazoxane (a type of Topoisomerase II Inhibitor) * Liposomal Doxorubicin (a type of Topoisomerase II Inhibitor) * Standard of care R-CHOP treatment regimen (Cyclophosphamide, doxorubicin, vincristine, prednisone, rituximab) * Standard of care pola-R-CHP treatment regimen: Cyclophosphamide, doxorubicin, polatuzumab vedotin-piiq, prednisone, rituximab
Interventions
- DRUG Cyclophosphamide
- DRUG Doxorubicin
- DRUG Liposomal Doxorubicin
- DRUG Dexrazoxane
- DRUG Dexrazoxane placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2026-10-02 |
| Est. Completion | 2035-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07654426
The ClinicalTrials.gov registry entry for NCT07654426 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT07654426 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07654426 about?
NCT07654426 is a clinical study titled "The CARDIOPROTECT Trial". This trial is to evaluate if dexrazoxane is safer and more effective than liposomal doxorubicin in preventing heart failure events in participants with diffuse large B-cell lymphoma (DLBCL) undergoing either standard of care R-CHOP or pola-R-CHP treatment regiments. The names of the study drugs inv...
What is the current status of trial NCT07654426?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2026-10-02. Estimated completion is 2035-12-31.
What interventions are being tested in trial NCT07654426?
The interventions under investigation include: Cyclophosphamide (DRUG), Doxorubicin (DRUG), Liposomal Doxorubicin (DRUG), Dexrazoxane (DRUG), Dexrazoxane placebo (DRUG).
Who is sponsoring clinical trial NCT07654426?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.